Bioanalytical Development and Validation of Liquid Chromatographic

Embed Size (px)

Citation preview

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    1/24

    Bioanalytical development and validation of liquid chromatographictandem mass

    spectrometric methods for the quantification of total and free cefazolin in human plasma and

    cord blood

    a b s t r a c t

    Objectives:

    Cefazolin is a commonly prescribed -lactam antibiotic for prophylais against s!in

    infections follo"ing surgery# including caesarean sections$ %ssessment of maternal and

    neonatal eposure is important for correlating drug concentrations to clinical outcomes$ &hus#

    bioanalytical methods for the quantification of both total and free cefazolin in maternal

    plasma and cord blood can assist in the comprehensive evaluation of cefazolin eposure$

    'esign and methods:

    (pecimen preparation for the measurement of total cefazolin "as performed via protein

    precipitation "ith acetonitrile containing the internal standard cloacillin$ )ltrafiltration "as

    used to isolate free cefazolin$ *rocessed samples "ere analyzed on a *relude (*+C system

    coupled to a &( ,triple quadrupole antage mass spectrometer$ .ethods "ere validated

    follo"ing /'% bioanalytical guidelines$

    0esults:

    &he analytical measuring ranges of these methods "ere 1$23231 mg4m+ and 1$12323

    mg4m+ for total and free drug# respectively$ Calibration curves "ere generated using 54 6

    "eighted linear regression analysis$ &otal cefazolin demonstrated inter- and intra-assay

    precision of 7 618 at the ++O, and 7 55$68 at other levels$ /ree cefazolin demonstrated

    inter-and intra-assay precision of 7 53$98 at the ++O, and 7 56$8 at other levels#

    respectively$ %ccuracy ;8'

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    2/24

    1. ?ntroductionCephalosporin antibiotics have become one of the mostcommonly prescribed classes

    of -lactams due to their broad spectrum of anti- bacterial activity# lo" toicity

    profile# and ease of administration A5#6$ Consequently# cephalosporins have been

    utilized for the treatment of a number of soft tissue and s!in infections in both

    perioperative and post-surgical settings# particularly as prophylactic agents A5#9$

    Cephalosporins are semi-synthetic compounds initially derived from the fungus

    Cephalosporium acremonium A$ (tructurally# these drugs are comprised of a -

    lactam moiety fused to a#-dihydro-6D-5#-thiazinering A5$ &here are several

    generations of cephalosporin antibiotics# and family members are stratfied based on

    their anti-bacterial activity and route of administration$

    Cefazolin# a first-generation cephalosporin# is "idely used to manage s!in infections#

    and has also sho"n therapeutic efficacy in the treatment of pulmonary infections and

    methicillin-susceptible (taphylococcusaureus AE#3$ +i!e other first-generation

    cephalosporins# cefazolin is effective intreating Fram-positive bacteria# but does not

    elicit equally effective bactericidal effects against Fram-negative bacteria A#>$

    .oreover# cefazolin has been administered prophylactically to prevent post-surgical

    s!in infections# including those incurred during cesarean deliveries A51#55$ Cesarean

    delivery is the primary ris! factor for postpartum maternal infections caused by Fram-

    positive bacteria# and studies have demonstrated that the infection rate in a post-

    cesarean setting can be as high as 38 A56$ Gotably# the prophylactic administration

    of cefazolin prior to s!in incision reduced post-cesarean morbidity as "ell asendometritis# and has been recommended by the %merican College of Obstetrics and

    Fynecology as a perioperative prophylactic agent during cesarean deliveries A555$

    Hhile the majority of the drug is predominantly protein bound by albumin ;I>18

    bound=# cefazolin elicits its antimicrobial effects in the unbound#or free# form A525$

    &hus# determination of both total and free cefazolin concentrations may be helpful in

    better characterizing the pharmaco!inetics of the cephalosporin in a variety of clinical

    scenarios# including in a post-cesarean setting$ Cefazolin quantification in the mother#

    as "ell as the neonate# can provide clarity on neonatal drug eposure# as "ell as its

    potential impact on post-delivery out comes# including the prevention of neonatalsepsis A5E$ Geonatal drug eposure measurement has been assessed in many matrices

    including urine# blood# meconium# hair# and umbilical cord blood$ )mbilical cord

    blood is a convenient matri to assess neonatal eposure because it should reflect

    recent changes in neonatal eposure at the time of delivery "ithout having to perform

    a venipuncture$

    Cefazolin quantification has been previously reporte dusing high performance liquid

    chromatographic ;D*+C= A5361 or liquid chromatographictandem masss

    pectrometric ;+C.(4.(= A6569 approaches$ Do"ever# none of the a for

    ementioned methods have etensively evaluated the acceptability of cord blood as amatri for cefazolin determination$Hhile several methods provide strategies for

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    3/24

    directly quantifying free drug concentration# only the methods published by

    Jhangetal$ A65 and 'ouglasetal$ A6 utilized tandem mass spectrometry as

    ananalytical detector A5361#66$ Dere "e present a comprehensive method

    describing the development and validation of +C.(4.( methods for the

    quantification of total and free cefazolin via ultrafiltration in plasma and cord blood$&he method use salo" volume of specimen for determination# requiring less than 691

    m+ for determination of both total cefazolin and free drug "ith in a sample$

    2. .aterials and methods6$5$ Chemicals

    Cefazolin ;>E8purity= as its sodium salt# its structural analogue cloacillin

    ;>28purity= as its hydrated sodium salt ;/ig$ 5=# and ethylene diamine tetra acetic acid

    ;1#6211# and

    23#111 mg4m+ in 5:5 acetonitrile : "ater$ Hor!ing solutions for the preparation of ,C

    materials "ere diluted into K611

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    4/24

    mg4m+ "as prepared by "eighing standard material and diluting volumetrically# and

    subsequent "or!ing stoc! solutions "ere prepared as previously described$ &hese

    "or!ing solutions "ere used to prepare ,C materials in plasma ultra filtrate at final

    concentrations of 1$123 ;++O,=# 1$52 ;lo" ,C=# 5$3 ;mid ,C=# and 25 ;high ,C=

    mg4m+$ ?nternal standard solutions "ere prepared in D*+C grade acetonitrile for totalcefazolin determination and D*+C grade "ater for free cefazolin determination at

    final concentrations of >$6 mg4m+ and5$3 mg4m+# respectively# by diluting a 5$3

    mg4m+ stoc! solution that "as prepared by "eighing cloacillin and diluting it

    volumetrically using 918 acetonitrile$

    6$$ (ample preparation

    6$$5$ &otal cefazolin

    &otal cefazolin concentrations in plasma and cord blood "ere determined after

    samples had been subjected to protein precipitation$ &"enty microliters of calibratoror

    ,C "as diluted 5 : 91 "ith acetonitrile at ambient temperature containing >$6 mg4m+

    cloacillinina /isherbrand 5$9 m+ polypropylene micro centrifuge tube ;Haltham#

    .%M final cloacillin concentration of >$1 mg4m+=$ &his miture "as vorteed for 9

    min using a (cientific ?ndustries orte Fenie 6 ;Bohemia# Ge"Nor!=$ %fter miing#

    samples "ere centrifuged at 5E#>65 g for 9 min using an

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    5/24

    ;Corning (*?G-P)/ 61 m+ capacity 51 !.H cut off concentration devices=$ *lasma

    "as added to spin devices and centrifuged at 529 g for 1 min using a &hermo

    (cientific Qouan C2 is "inging buc!et centrifuge ;(an Qose# C%=$ )ltrafiltrate "as

    pooled from collections and used in the preparation of the calibrators and ,C

    materials$

    6$9$ ?nstrument and acquisition parameters

    Chromatographic separation "as performed on the &hermo (cientific *relude (*+C

    system ;(an Qose# C%= operating in laminar only mode ;+P=$ (pecimens "ere

    maintained at 2 5C in a C&C*%+ autosampler ;Carrboro# GC=$ Cefazolin and its

    structural analog "ere chromatographically separated using a *henomene Kinete

    C3 ;91I6$5 mm6# 5$E mm particle size= column ;&orrance# C%= maintained at 21C$

    &he mobile phase system consisted of "ater containing 68 acetonitrile and 1$58

    formic acid ;mobile phase %# .*%= and a cetonitrile containing 1$58 formic acid

    ;mobile phase B# .*B=$ % third solvent consisting of 29:29:51 acetonitrile :

    isopropanol : acetone "as introduced to the analytical column during the "ash step$

    &o reduce carry over#51 + of 5 m. e= and 2E-51 m4z ;C< : 59e=# respectively$

    6$$ 'ata evaluation

    Pcalibur 6$6 soft"are ;&hermo (cientific= "as used for data acquisition and

    processing$ Calibration curves "ere generated using linear regression "ith 546

    "eighting and pea! areas generated after Faussian smoothing using the Fenesis

    integration algorithm$.icrosoft Office

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    6/24

    Chromatographic conditions for the determination of cefazolin and free cefazolin$

    Coefficient of variation ;8 C= is defined belo"#"here S is the standard deviation

    and is the average concentration observed$

    8 '

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    7/24

    Concentrations determined "ere those generated from the calibration curve performed on

    each run$

    $6$ Carryover

    Carryover "as determined by alternating injections of lo" ;+= concentration calibrator

    ;either 1$23 or 1$123 mg4m+ for cefazolin or free cefazolin# respectively= and high ;D=

    concentration calibrator ;either 251 or 25 mg4m+ for cefazolin or free cefazolin#

    respectively= and comparing the mean concentration of the lo" calibrators injected prior

    to high calibrator to those injected after$ (pecifically#calibrators "ere injected in the order

    : +5# +6# +# D5# D6# +2# D# D2# +9# +# +E# +3# D9# D# +># DE# D3# +51# D># D51#

    and +55$ %cceptability criteria "ere mean post-high injection levels L(' greater than

    pre-high injection levels$ &hese acceptability criteria are consistent "ith C+(? protocol

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    8/24

    .atri effects "ere evaluated by there covery ratio of post- etracted:

    unetractedM recovery efficiency "as evaluated by there covery ratio of pre-

    etracted: post-etractedM processing efficiency "as evaluated by there covery

    ratio of pre-etracted: unetracted$

    $9$ Cord blood comparison

    &he described +C.(4.( method "as also used to assess drug quantification of

    total cefazolin in cord blood and free cefazolinin cord blood ultrafiltrate#

    respectively$ %cceptability of quantifying drug concentrations in cordblood from

    an adult human plasma ;non-cord blood= calibration curve "as determined by

    calculating 8'?/ of lo"# mid# and high ,C levels as compared to adult plasma

    ,C material analyzed on the same calibration curve$ Cefazolin "or!ing solutions

    for the preparation of ,C materials for total and free cefazolin "ere used to

    generate equivalent concentration materials in both cord blood plasma and plasma

    ultrafiltrate$ Cord blood plasma ultrafiltrate "as prepared using the same protocolfor determination of free cefazolin: briefly# Corning ultrafiltration devices "ere

    implemented for the filtration of 611 m+ sample$ % pool of ultrafiltrate "as

    generated for the preparation of ,C materials$ Cord blood materials "ere prepared

    at the same lo"# mid# and high ,C concentrations as prepared for total and free

    cefazolin determination$ %cceptability limits "ere defined as 7U598'?/ from

    material prepared in human plasma or human plasma ultrafiltrateM this

    acceptability threshold has been implemented for stability-challenged samples#

    and "as thus applied "hen comparing plasma and cord blood results$

    2$ 0esults and discussion

    2$5$+iquid chromatographictandem mass spectrometric ;+C.(4.(= parameters

    Cefazolin "as chromatographically separated from matri components under a

    gradient elution profile "ith a *henomene Kinete C3 column ;&able5 and /ig$ 6=$

    )sing the described method# cefazolin and cloacill in eluted at 5$9 and 6$1 min#

    respectively$ &he *henomene Kinete C3 column is a sub-6 mm porous particle

    column that lend sit self to clinical applications because of fast# sharp pea!s and

    moderate bac! pressure A6>$ 'ue to the lac! of availability of isotopically labeled

    cefazolin# a -lactam structural analogue# cloacillin# "as used as an internal standard$Other methods described for cefazolin analys is also used structural analogues as

    internal standards A669$ %cetonitrile "as chosen as mobile phase Basit

    demonstrated higher ionization efficiency than methanol ;data not sho"n=$ &he

    addition of

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    9/24

    method$ &he strong "ash solvent "as introduced using a second binary pump "ith as

    "itching valve and a tee into the analytical column$

    Optimized ionization source and mass spectrometry parameters for cefazolin and

    cloacillin "ere determined by manually adjusting conditions during direct infusion$

    Both compounds "ere analyzed in their protonated A. V DVforms$ (elected reaction

    monitoring ;(0.= mode ion transitions "ere selected on the basis of signal intensity

    and imprecision during suitability eperiments$ .oreover# though the molecular

    formula of these fragment ions "as not confirmed "ith labeling studies# their masses

    indicate they are not products of common losses ;condensation# decarboylation# etc$=

    and may contain the tetrazole ring#"hich is the characteristic 06moiety for cefazolin$

    Chromatograms generated from qualifier ion transitions "ere evaluated on the basis

    of their pea! shape$ %pplication of qualifier transitions is especially important "hen

    utilizing a structural analogue as an internal standard for quantitative mass

    spectrometry$ One major consequence of a structural analogue as an internal standardis that it often does not co-elute "ith the analyte$ *otential interferences may cause

    ion suppression and significantly affect the accuracy of results$

    &he method published by 'ouglasetal et al$ used in vivo microdialysis to determine

    free cefazolin concentrations# "hich is impractical for routine clinical testing A6$

    &he method published by Jhangetal et al$ presented a relatively comprehensive

    validation for determining total and free cefazolin in human plasma# but did not

    provide details on comparative studies in cord blood# nor did it provide details on

    ?mproving analytical selectivity through the introduction of a qualifier ion transitionA65$

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    10/24

    /ig 6$ 0epresentative chromatograms for ;%= cefazolin ++O, lo" ,C and blan!

    palasma and ;B= cloacillin internal standard and blan! plasma$

    /ig $ 0epresentative chromatograms of carryover oprimization sequences$

    Chromatograms from ;%= are prior to optimization$ Chromatograms from ;B= are

    post-optimization$

    2$6$ *recision# accuracy and calibration curve analysis

    ?ntra - and inter-assay precision and accuracy for total cefazolin and free cefazolin

    "ere determined follo"ing there commendations of the /'% guide lines as previously

    described ;&able6=$ &otal cefazolin intra-assay precision ranged from $68 to

    61$18C at the ++O,$ ?ntra- assay accuracy as 8'$58 at the ++O,$ ?nter-

    assay accuracy as 8'8$ /ree cefazolin intra-assay

    precision ranged from E$68 to 5E$38 at the ++O,$ /ree cefazolin intra-assay

    accuracy ranged from I$E8 to $28$ /ree cefazolin inter-assay precision ranged

    from 9$E8 to 53$98 and inter-assay deviation ranged from I5$>8 to 6$98$ %ll

    observed results "ere acceptable for all ,C levels$ &he %.0s of the assays "ere

    1$23231 mg4m+ for total cefazolin and 1$12323 mg4m+ for free cefazolin ;/ig$ 2

    and data not sho"n=$ &he %.0s are sufficiently dynamic and encompass typical

    cefazolin concentrations observed follo"ing standard dosing# as total cefazolin

    plasma concentrations typically achieve levels I5$2525 mg4m+ A66$ &he %.0 "as

    epanded I-fold beyond this limits to account for unepected over-dosing# under-

    dosing# as "ell as studies that adjust the timing of dosing$ (tandard dosing protocolsinclude56 g cefazolin t$i$d$ for treatment of infections or 56 g single dose for

    prophylais during surgery A6#5#6$ &he analytical measuring range of unbound

    cefazolin spans 5 order of magnitude less than the analytical measuring range for total

    cefazolinM this is consistent "ith plasma protein binding resulting in free

    concentrations 518 of total concentrations A$ Both assays utilized standard curves

    constructed using 546 "eighted linear regressions of the pea! area ratio of cefazolin

    and cloacillin relative to the cefazolin concentration of calibrators$ &he standard

    curve intercepts and linear coefficients "ere used to determine total cefazolin and free

    cefazolin concentrations in quality control materials and un!no"n specimens$ &he

    average correlation coefficient 06 for regression fittings "as W 1$>> ;/ig$ 2=$ &he

    upper limit of quantification "as determined by observing the highest concentration

    that provided a linear calibration curve# in this method that concentration ;231 or 23

    mg4m+ for total cefazolin and free cefazolin= provided an analytical measuring range

    of three orders of magnitude$ &he upper end of the calibration curve does appear to

    slightly under-recover# as reflected by the high ,C bias of IE$E8# but this small value

    "as still "ith in the acceptability criterion defined by /'% Bioanalytical .ethod

    alidation guidelines$ %doption of an isotopically labeled internal standard of

    cefazolin may mitigate this bias$

    Table2 Inter-assay and intra-assay precision and accuracy

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    11/24

    Fig. 4. Representative calibration curves for total cefazolin analysis.

    The y-axis of !" is the pea# area ratio observed bet$een cefazolin

    and cloxacillin %uantifier transitions. The y-axis of &" is the

    calculated concentration using linear regression.

    2$$ Carryover

    Carryover analysis "as conducted according to C+(? guidelines by evaluating the

    determined average concentration of lo" concentration standards injected in

    alternating series "ith high concentration standards A6E$ Overcoming issues

    "ithcarryover "as critical during method development because of the broad dynamic

    range of the method$ Carryover "as not noticed "hen observing analogous signal of

    the cloacill in internal standard# suggesting potential accumulation of cefazolin in the

    (*+C system at high concentrations$ Based on these observations# astringent "ash of

    29:29:51 acetonitrile : 6-propanol : acetone "as introduced during the "ash step as

    "ell as introducing

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    12/24

    ;7 U 598 '?/=$ Do"ever# the freezetha" cycle data all indicate negative differences#

    "hich suggest some instability of the analyte to sustain freetha" cycles# leading to

    degradation$

    2$9$ (electivity and matri effects

    Go pea!s "ere observed near the retention times for cefazolin or cloacillin in blan!

    plasma ;/ig$ 6=$ .oreover# si independent lots of human plasma "ere evaluated in

    the process and sho"ed no interfering pea!s ;data not sho"n=$ .atri effects "ere

    evaluated by comparing pea! area signals generated from cefazolin spi!ed into "ater

    ;unetracted= and processed according to the protocol# cefazolin spi!ed into plasma

    and processed according to protocol ;pre-etracted=# or spi!ed into blan! plasma

    etract ;post-etracted=$ .atri effects are determined by comparing the apparent

    signal from post-etracted material to unetracted material$ &here covery efficiency

    for matri effects at lo"# mid# and high ,C level sranged 33$951$8 for cefazolin

    and >5$E>3$>8 for cloacillin ;&able 2=$ % teach ,C level# there is less than 518

    difference in overall matri effects bet"een cefazolin and cloacillin# further

    supporting the use of cloacillin as an internal standard$ 0ecovery efficiency "as

    determined by comparing the pea! area intensities of pre-etracted material to post-

    etracted material$ &hese recoveries ranged from E2$8 to 3E$>8 for cefazolin and

    515$28 to 51E$8 for cloacillin$ ?t is epected for recovery of cefazolin to be less

    than that of cloacillin as cefazolin must be isolated from the plasma matri# "hereas

    the internal standard is in solvent$ *rocessing efficiency "as evaluated by comparing

    pre-etracted material to un-etracted material$ &here coveries ranged from 3$E8 to

    >$E8 for cefazolin and >8 to 518 for cloacillin$ &he overall processing

    efficiency for cefazolin reflects the minimal matri effects seen in addition to the

    decreased recovery from plasma$ Do"ever# as there are no relative matri effects and

    cefazolin concentrations are determined by the pea! area ratio of drug to internal

    standard# the method may be used for cefazolin quantification$

    2$$ Cord blood comparison

    ?n lieu of full validation by preparing calibration and quality control material sets in

    cord blood#"e validated its acceptability as a specimen matri by evaluating recovery

    of cefazolin spi!ed directly into cord blood or cord blood ultrafiltrate$ &heseconcentrations "ere determined using calibration curves generated using total

    cefazolin calibrators in human plasma or free cefazolin calibrators in human plasma

    ultrafiltrate for total cefazolin and free cefazolin# respectively$ &he values determined

    from the cord blood plasma quality control materials "ere compared to the values

    determined from plasma and plasma ultrafiltrate$ &he difference from the t"o values

    "as calculated and a 8'?/ "as determined# "ith an acceptability criteria of 7U598$

    &he relative recovery for cefazolinin cord blood and cord blood ultrafiltrate ranged

    I2$>8 to >$58 for total cefazolin and I5$28 to I55$>8 for free cefazolin ;&able9=$

    &hese values "ere "ithin our limit of acceptability of rU598'?/$ &hese resultssuggest that cord blood plasma and cord blood plasma ultrafiltrate may be analyzed

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    13/24

    along side plasma and plasma ultrafiltrate specimens using the a for ementioned

    conditions described in the protocol$ &his is the first demonstration verifying

    acceptability for analysis of both total and free cefazolinin plasma and plasma

    ultrafiltrat eas "ell as cord blood plasma and cord blood plasma ultrafiltrate$

    &he described +C.(4.( methods facilitate the quantification of total and free

    cefazolin in both adult and cord blood plasma$ &hese methods ta!e advantage of

    convenient ultrafiltration techniques for separating the free drug from plasma

    proteins$ &he methods are fast at 9 min per analysis and only require61 l of plasma

    for determination of total cefazolin and 611 l of plasma for determination of free

    cefazolin$ Do"ever# there are some limitations to the described methods$ &he steps

    required to achieve satisfactory carryover performance "ith additional "ash steps that

    could be prohibitive if the D*+C does not easily facilitate introduction of strong "ash

    solvent during an analysis$ %nother limitation is the necessity of consuming a nultra

    filtration device for assessing free cefazolin concentrations$ &he free cefazolin methoduses standard ultrafiltration condition store move plasma proteins# but the calibrators

    and quality control materials "ere prepared directly in plasma ultrafiltrate$ ?deally# a

    method "ould utilize "ell-characterized materials of !no"n free drug concentrationas

    calibrators and quality controls$ %dditionally# alternative methods to ultrafiltration#

    such as rapid equilibrium dialysis# may reduce the amount of technician time required

    for analysis$ .oreover# these method shave not been compared to a reference

    laboratory due to a lac! of testing availability$ +astly# "e have not evaluated the

    described methods in a patient cohortM this "ill be performed in forthcoming studies$

    &able 2

    &otal cefazolin matri effects studies describing recoveries for the analyte cefazolin

    ;C/J= and cloacillin ;C+P=$

    2$ Conclusions

    % rugged +C.(4.( method for the quantification of total and free cefazolin in both

    adult and cord blood plasma has been developed and validated$

    %c!no"ledgments

    &his "or! "as supported in part by the &hermo /isher (cientific through are search

    contract and placement of instrumentation$

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    14/24

    penge'bangan bioanalitis dan validasi cair #ro'atogra(-tande' 'etode

    spe#tro'etri 'assa untu# #uanti(#asi total dan bebas cefazolin dala'

    plas'a 'anusia dan darah tali

    abstra#

    tu)uan*+efazolin adalah ,-la#ta' antibioti# u'u'nya diresep#an untu#

    pro(la#sis terhadap infe#si #ulit setelah operasi ter'asu# operasi caesar.

    enilaian paparan ibu dan bayi penting untu# 'enghubung#an #onsentrasi

    obat untu# hasil #linis. /engan de'i#ian 'etode bioanaliti# untu#

    #uanti(#asi bai# total dan bebas cefazolin dala' plas'a dan su'su' ibu

    darah dapat 'e'bantu dala' evaluasi 'enyeluruh paparan cefazolin.

    /esain dan 'etode*

    persiapan spesi'en untu# pengu#uran total cefazolin dila#u#an 'elalui

    presipitasi protein dengan asetonitril 'engandung cloxacillin standar

    internal. 0ltra(ltrasi diguna#an untu# 'engisolasi cefazolin gratis. sa'peldiproses dianalisis pada siste' + relude digabung#an #e

    spe#tro'eter 'assa T 3triple %uadrupole antage. 5etode yang

    divalidasi pedo'an bioanalitis F/! beri#ut.

    hasil*

    Rentang pengu#uran analisis dari 'etode ini adalah 46-467 'g 8 ' dan

    7746-46 'g 8 ' untu# obat bebas dan total 'asing-'asing. #urva

    #alibrasi yang dihasil#an 'engguna#an 1 8 x2 analisis regresi linear

    terti'bang. Total cefazolin 'enun)u##an antar dan intra-assay presisi 9

    27: di ;3 dan 9 112: pada ting#at lain. cefazolin bebas 'enun)u##an

    inter-dan intra-assay presisi 9 16" a#u'ulasi efe# 'atri#s pe'ulihan

    dan stabilitas studi )uga diteri'a berdasar#an re#o'endasi F/!.

    elan)utnya itu 'enun)u##an bah$a sa'pel disiap#an dala' darah tali

    dapat secara a#urat diu#ur dari #urva #alibrasi plas'a de$asa dengan

    pe'ulihan 9 ?1: /IF dan 9 11?: /IF total dan bebas cefazolin 'asing-

    'asing.

    #esi'pulan*

    'etode +-5 8 5 yang di)elas#an 'e'ung#in#an untu# pengu#uran

    total dan bebas cefazolin di #edua plas'a dan darah tali pusat. @ 271/T! plas'a$ith solusi saha'

    yang tepat. Konsentrasi 'encer'in#an #uantitas cefazolin gara' natriu'

    dala' larutan. Total volu'e organi# dita'bah#an #e plas'a adalah L2:.

    #ontrol #ualitas 3+" bahan disusun 'engguna#an solusi be#er)a disiap#an

    dari independen berat dari solusi yang diguna#an untu# 'enyiap#anstandar #alibrasi. solusi be#er)a untu# persiapan bahan 3+ disiap#an pada

    #onsentrasi 1?72477 dan 46.777 'g 8 ' dala' 1* 1 asetonitril* air.

    &e#er)a solusi untu# persiapan bahan 3+ diencer#an dala' K2>/T!

    plas'a pada #onsentrasi a#hir 746 batas ba$ah dari #uanti(#asi ;3"

    14 3+ rendah" 167 pertengahan 3+" dan 417 tinggi 3+" 'g 8 '.

    +efazolin solusi be#er)a untu# penyusunan standar #alibrasi disiap#an

    untu# penentuan cefazolin gratis dengan a$alnya 'e'persiap#an

    asolution 1?77 'g 8 ' cefazolin di 1* 1 asetonitril* air dengan

    'eni'bang bahan standar dan 'enipis#an volu'etrically. solusi be#er)a

    disiap#an pada #onsentrasi a#hir 71? 'g 8 ' 1? 'g 8 ' dan 1?7 'g 8' 'elalui pengenceran serial. standar #alibrasi yang preparedat

    #onsentrasi a#hir 7746 7.7?

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    17/24

    D+ #elas total cefazolin te#ad dan air #elas D+ untu# cefazolin

    penentuan gratis pada #onsentrasi a#hir ?2 'g 8 ' and1.6 'g 8 '

    'asing-'asing dengan cara pengenceran 16 'g 8 ' larutan sto# yang

    disiap#an dengan 'eni'bang cloxacillin dan 'enca'purnya

    volu'etrically 'engguna#an

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    18/24

    bahan 3+.

    2.

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    19/24

    punca# dengan #onsentrasi #alibrator.

    : /IF dide(nisi#an di ba$ah ini di 'ana x Referensi adalah rata-rata

    diu#ur #onsentrasi bahan 3+ dala' #ondisi referensi dan x /iobati adalah

    #onsentrasi rata-rata diu#ur untu# ting#at 'ateri 3+ yang sa'a

    diperla#u#an berbeda.

    : 5>: > dan: R> disa)i#an sebagai pe'ulihan relatif di 'ana x1adalah intensitas punca# daerah berte#ad rata-rata untu# pengobatan

    referensi untu# #o'ponen cefazolin o rcloxacillin" ditentu#an dari bahan

    3+ dan x2 adalah rata-rata daerah pera$atan tes intensitas untu# bahan

    3+. 5isalnya dala' 'enentu#an efe# 'atri#s cefazolin x1 adalah

    intensitas rata-rata luas untu# cefazolin dala' persiapan tere#stra#si dan

    x2 adalah intensitas rata-rata luas untu# cefazolin dala' bahan pasca

    die#stra#si.

    C. 5etode validasi

    5etode +-5 8 5 telah divalidasi berdasar#an F/! edo'an untu#

    Industri* re#o'endasi &ioanalytical alidasi 5etode A2=B. 'etri# validasiter'asu# intra dan inter-assay presisi dan a#urasi linearitas stabilitas

    a#u'ulasi dan efe# 'atri#s. ara'eter ini sepenuhnya ditandai total

    cefazolin dala' plas'a 'anusia. cefazolin gratis divalidasi di ultra(ltrate

    plas'a 'anusia dengan 'engatasi presisi a#urasi dan a#u'ulasi. darah

    tali dievaluasi dengan 'engu#ur pe'ulihan darah tali cefazolinin dan

    #abel ultra(ltrate darah dibubuhi cefazolin dari #urva #alibrasi yang

    disiap#an di non-#abel plas'a darah.

    C.1. resisi dan a#urasi

    Intra-assay presisi ditentu#an dengan in)e#si ulangan n S =" total ataubebas bahan cefazolin 3+ pada e'pat ting#at. /ia'ati berarti / dan:

    + dinilai pada setiap ting#at. The ;3 dide(nisi#an sebagai #alibrator

    terendah pada #urva #alibrasi dan sesuai dengan re#o'endasi F/!

    'enghasil#an a#urasi dan presisi #riteria 9 27: /> dari #onsentrasi

    teoritis dan #etida#tepatan dari 9 27: +. Target untu# ting#at atas ;3

    yang 9 1 dari #onsentrasi teoritis dan #etida#tepatan dari 91

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    20/24

    41 'g 8 ' untu# cefazolin atau cefazolin gratis 'asing-'asing" dan

    'e'banding#an #onsentrasi rata-rata dari #alibrator rendah disunti##an

    sebelu' #alibrator tinggi #e disunti##an setelah. ecara #husus #alibrator

    disunti# dala' urutan* 1 2 C D1 D2 4 DC D4 17-!2 A2EB.

    elain itu /urin analisis groutine sunti#an pelarut ! 71: asa' for'at"

    diin)e#si setelah penyunti#an dari #alibrator #onsentrasi tertinggi. Kriteria

    peneri'aan adalah pasca-in)e#si sinyal #osong diu#ur sebagai daerah

    punca# #ro'atogra( L27: dari sinyal yang dia'ati untu# #alibrator

    #onsentrasi terendah.

    C.C. tabilitas

    tudi stabilitas dila#u#an untu# #eseluruhan analisis cefazolin. Rendah

    'enengah dan ting#at 3+ yang tinggi 'en)adi sasaran stabilitas 'atri#sin)e#si stabilitas sa'pel 'atri#s dan freeze-tha$ stabilitas. In)e#si

    'atri#s percobaan stabilitas dila#u#an oleh e#stra# 3+ ulang 'enganalisis

    dipertahan#an pada 4+ e'pat hari setelah persiapan dengan #alibrator

    ulang 'enganalisis dan bahan 3+ 'engu#ur atas dasar #urva #alibrasi

    baru dan dibanding#an dengan nilai-nilai asli. a'pel 'atri#s percobaan

    stabilitas dila#u#an dengan 'enganalisis bahan #ontrol #ualitas setelah

    in#ubasi sela'a 24 )a' pada suhu #a'ar. Freeze-tha$ percobaan

    stabilitas dila#u#an dengan 'e'banding#an baru dibanding#an bahan

    #ontrol #ualitas untu# 'ateri yang telah 'en)alani n S 4 si#lus be#u-

    'encair 'engguna#an freezer dipertahan#an pada 27+. percobaanstabilitas saha' dila#u#an di 'ana solusi saha' diin#ubasi pada suhu

    #a'ar 4+ dan 27+ sela'a C 'inggu. eneri'aan ditentu#an sebagai L

    1fe# 5atrix pada

    ionisasi dinilai dengan 'engguna#an 'etode yang sebelu'nya di)elas#an

    oleh 5atusze$s#i dan re#an A26B 'engguna#an set bahan 3+ disiap#an

    pada rendah 'enengah dan #onsentrasi tinggi. &ahan-bahan inidisiap#an untu# analisis dala' tiga set independen* tere#stra#si pra-

    die#stra#si dan pasca-die#stra#si. ecara sing#at sa'pel tere#stra#si

    disusun 'engguna#an proto#ol di)elas#an tapi 'engganti 5! 71: asa'

    for'at" di te'pat plas'a sa'pel pra-die#stra#si 'engandung #adar 3+

    'elon)a# 'en)adi plas'a dari ena' banya# individu dan satu set pasca-

    die#stra# yang 'elibat#an pena'bahan solusi spi#ing #e pasca die#stra#

    'atri#s plas'a dari tersebut ena' banya# independen. Konsentrasi (nal

    di rendah 'enengah dan tinggi 3+s dipertahan#an di se'ua tiga set.

    Hilai daerah punca# ba#u yang dihasil#an oleh analisis ini dibanding#an

    dengan 'enghitung efe# 'atri#s e(siensi pe'ulihan dan e(siensipengolahan. Ku'pulan individu: Ri$ayat Didup )uga ditentu#an. >fe#

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    21/24

    5atrix dievaluasi oleh rasio covery ada dari pasca die#stra#* tere#stra#siM

    e(siensi pe'ulihan dievaluasi dengan rasio covery ada pra-die#stra#si*

    pasca-die#stra#siM e(siensi pengolahan dievaluasi dengan rasio covery

    ada pra-die#stra#si* tere#stra#si.

    C.

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    22/24

    ecessity untu# 'encapai rentang pengu#uran analitis tepat dina'is

    !5R" 'enga#ibat#an 'odi(#asi beri#utnya dengan 'etode +. elarut

    $ash #uat diper#enal#an 'engguna#an po'pa biner #edua dengan #atup

    sebagai 'e'pesona#an dan tee #e dala' #olo' analitis.

    /iopti'al#an su'ber ionisasi dan para'eter spe#tro'etri 'assa untu#

    cefazolin dan cloxacillin ditentu#an dengan 'enyesuai#an #ondisi 'anualsela'a infus langsung. Kedua senya$a dianalisis di A5 U DB terprotonasi

    'ere#a U bentu#. Rea#si yang dipilih pe'antauan 'odus R5" transisi

    ion yang dipilih atas dasar intensitas sinyal dan #etida#tepatan sela'a

    percobaan #esesuaian. elain itu 'es#ipun ru'us 'ole#ul dari ion-ion

    frag'en tida# di#on(r'asi dengan studi pelabelan 'assa 'ere#a

    'enun)u##an 'ere#a bu#an produ# dari #erugian u'u' #ondensasi

    de#arbo#silasi dll" dan 'ung#in berisi cincin tetrazol yang 'erupa#an

    bagian R2 #ara#teristi# untu# cefazolin . Kro'atogra' yang dihasil#an

    dari transisi ion #uali(#asi dievaluasi atas dasar bentu# punca# 'ere#a.

    enerapan transisi #uali(#asi sangat penting #eti#a 'engguna#an analogstru#tural sebagai standar internal untu# spe#tro'etri 'assa #uantitatif.

    alah satu #onse#uensi uta'a dari analog stru#tural sebagai standar

    internal adalah bah$a hal itu sering tida# #o-elusi dengan analit. otensi

    gangguan dapat 'enyebab#an pene#anan ion dan secara signi(#an

    'e'pengaruhi #ea#uratan hasil.

    5etode yang diterbit#an oleh /ouglasetal et al. diguna#an in vivo

    'icrodialysis untu# 'enentu#an #onsentrasi cefazolin gratis yang tida#

    pra#tis untu# pengu)ian #linis rutin A2CB. 5etode yang diterbit#an oleh

    Jhangetal et al. disa)i#an validasi yang relatif #o'prehensif untu#

    'enentu#an cefazolin total dan bebas dala' plas'a 'anusia tetapi tida#'e'beri#an rincian tentang studi banding dala' darah tali pusat )uga

    tida# 'e'beri#an rincian tentang

    5ening#at#an sele#tivitas analitis 'elalui pengenalan transisi ion

    #uali(#asi A21B. >valuasi transisi ion #uali(#asi 'ena'bah spesi(sitas

    analisis ta'bahan untu# 'etode spe#tro'etri 'assa #arena gangguan

    'ung#in 'e'ili#i e(siensi diferensial untu# 'enghasil#an sinyal untu#

    transisi diVerention. +ord darah se'entara tida# 'atri#s independen

    divalidasi dala' hal presisi dan a#urasi penelitian untu# 'enilai setiap

    interferents potensial pada #uanti(#asi obat dan untu# lebih 'enciri#an

    #e#asaran #eseluruhan 'etode analisis. 5etode ini divalidasi'engguna#an garis panduan F/! 5etode &ioanalytical alidasi #arena itu

    adalah satu set 'apan pedo'an coco# untu# studi far'a#o#ineti# yang

    a#an 'en)adi apli#asi uta'a untu# pengu)ian tersebut.

    0ltra(ltrasi dipilih untu# 'engisolasi fra#si bebas dari cefazolin #arena

    cepat relatif 'urah untu# 'enerap#an pada s#ala studi yang terbatas

    dan hanya re%uiresa centrifuge 'i#ro yang u'u'nya tersedia dala'

    penelitian #linis laboratory.The standar internal dita'bah#an #e

    ultra(ltrate dari diproses 'aterial #arena pena'bahan bahan sebelu'

    (ltrasi a#an 'engganggu #esei'bangan siste'. !saresult #a'i

    'engguna#an #ondisi (ltrasi standar teruta'a yang dirancang untu#'enyaring albu'in untu# sa'pel fra#si bebas dari cefazolin

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    23/24

    'engguna#an ultra(ltrasi. The topicin u'u' telah dievaluasi dala'

    literatur #hususnya dala' penerapan fenitoin penentuan gratis dengan

    i''unoassay beri#ut ultra(ltrasi AC7B.

    #ro'atogra' a'bar 2. er$a#ilan !" cefazolin ;3 rendah palas'a

    3+ dan #osong dan &" internal standar cloxacillin dan plas'a #osong.

    #ro'atogra' a'bar C. er$a#ilan dari urutan opri'ization a#u'ulasi.Kro'atogra' dari !" yang sebelu' opti'asi. Kro'atogra' dari &"

    adalah pasca-opti'asi.

    4.2. resisi a#urasi dan analisis #urva #alibrasi

    Intra - presisi dan antar-assay dan a#urasi total cefazolin dan cefazolin

    gratis ditentu#an beri#ut ada pu)ian dari garis panduan F/! seperti

    di)elas#an sebelu'nya Tabel 2". Total cefazolin intra-assay presisi ber#isar

    dari =2: 'en)adi 277: + di ;3 itu. Intra a#urasi assay sebagai:

    /> ber#isar antara G4.C: 'en)adi 146:. Total cefazolin antar-assay

    presisi ber#isar dari =2: 'en)adi 1?1: di ;3 itu. !ntar a#urasi assay

    sebagai: /> ber#isar antara GE.E: 'en)adi 11?:. ratis cefazolinintra-assay presisi ber#isar antara E2: sa'pai 1E6: di ;3 itu. ratis

    cefazolin a#urasi intra-assay ber#isar antara G=.E: 'en)adi C4:. ratis

    cefazolin antar-assay presisi ber#isar dari

  • 7/25/2019 Bioanalytical Development and Validation of Liquid Chromatographic

    24/24

    Table2 Inter-assay dan intra-assay presisi dan a#urasi

    !ra. 4. #urva #alibrasi er$a#ilan total analisis cefazolin. N-su'bu !"

    adalah rasio luas punca# dia'ati antara cefazolin dan cloxacillin %uanti(er

    transisi. N-su'bu &" adalah #onsentrasi dihitung 'engguna#an regresi

    linear.

    4.C. 5enopanganalisis a#u'ulasi dila#u#an sesuai dengan pedo'an +I dengan

    'engevaluasi #onsentrasi rata-rata ditentu#an standar #onsentrasi rendah

    disunti##an di bola# seri dengan standar #onsentrasi tinggi A2EB.

    5engatasi 'asalah $ithcarryover #ritis sela'a penge'bangan 'etode

    #arena rentang dina'is yang luas dari 'etode ini. uncuran tida# 'elihat

    #eti#a 'enga'ati sinyal analog dari cloxacill di internal standard

    'enun)u##an potensi a#u'ulasi cefazolin dala' siste' + pada

    #onsentrasi tinggi.

    4.4. tabilitas

    4.